Replimune Group, Inc. (NASDAQ:REPL – Get Rating) – Equities researchers at Wedbush lowered their FY2024 EPS estimates for Replimune Group in a report issued on Monday, May 22nd. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($3.95) for the year, down from their prior estimate of ($3.23). The consensus estimate for Replimune Group’s current full-year earnings is ($2.91) per share. Wedbush also issued estimates for Replimune Group’s Q4 2024 earnings at ($1.11) EPS, FY2025 earnings at ($4.91) EPS, FY2026 earnings at ($3.44) EPS, FY2027 earnings at ($0.30) EPS and FY2028 earnings at $3.40 EPS.
A number of other research firms also recently weighed in on REPL. Piper Sandler reaffirmed an “overweight” rating and set a $44.00 price target on shares of Replimune Group in a research note on Monday, April 17th. HC Wainwright raised their target price on shares of Replimune Group from $48.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, February 10th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Replimune Group presently has an average rating of “Buy” and an average price target of $51.60.
Replimune Group Stock Down 2.3 %
Institutional Trading of Replimune Group
Institutional investors have recently made changes to their positions in the stock. TD Asset Management Inc lifted its stake in shares of Replimune Group by 26.6% in the 4th quarter. TD Asset Management Inc now owns 132,963 shares of the company’s stock worth $3,617,000 after acquiring an additional 27,962 shares during the period. Victory Capital Management Inc. acquired a new position in Replimune Group in the 4th quarter valued at approximately $15,680,000. Emerald Advisers LLC increased its stake in Replimune Group by 4.4% in the 4th quarter. Emerald Advisers LLC now owns 1,186,041 shares of the company’s stock valued at $32,260,000 after buying an additional 49,455 shares during the period. Fisher Asset Management LLC acquired a new position in Replimune Group in the 3rd quarter valued at approximately $954,000. Finally, Sectoral Asset Management Inc. acquired a new position in Replimune Group in the 4th quarter valued at approximately $5,345,000. 87.83% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In related news, CEO Philip Astley-Sparke sold 17,902 shares of the business’s stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $18.05, for a total transaction of $323,131.10. Following the completion of the sale, the chief executive officer now owns 1,525,278 shares of the company’s stock, valued at approximately $27,531,267.90. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, CFO Jean M. Franchi sold 11,351 shares of the company’s stock in a transaction that occurred on Tuesday, May 16th. The shares were sold at an average price of $18.05, for a total value of $204,885.55. Following the completion of the sale, the chief financial officer now directly owns 128,748 shares of the company’s stock, valued at approximately $2,323,901.40. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Philip Astley-Sparke sold 17,902 shares of the company’s stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $18.05, for a total transaction of $323,131.10. Following the completion of the sale, the chief executive officer now directly owns 1,525,278 shares of the company’s stock, valued at $27,531,267.90. The disclosure for this sale can be found here. Insiders sold a total of 55,603 shares of company stock valued at $1,003,634 in the last ninety days. Corporate insiders own 23.80% of the company’s stock.
Replimune Group Company Profile
Replimune Group, Inc is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm’s Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response.
- Get a free copy of the StockNews.com research report on Replimune Group (REPL)
- Toll Brothers Rises On Results, But The Roof Is In Place
- It’s Time To Try On VF Corporation’s 6% Yield
- PetCo Management Getting it Right? Earnings Beat Says Yes
- Axcelis Stock In Buy Range After Chart Breakout, Strong Guidance
- Kohl’s 10% Yield Comes Into High Fashion
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.